APOE and Alzheimer disease: Although LXR and Retinoid X receptor (RXR) agonists have proven efficacy to upregulate genes involved in ApoE-lipidation (like ABCA1 or ABCG1), improve Aβ clearance, and reverse memory deficits in animal models of AD, they produce unwanted peripheral effects on triglyceride levels and liver health.